Evidence map›Paper›PMID 40532477›Full record

ArticleVaccine2025

Development of an efficacious oral peptide vaccine against infection with the carcinogenic liver fluke Opisthorchis viverrini.

Wuttipong Phumrattanaprapin, Ahmed O Shalash, Mariusz Skwarczynski, Michael J Smout, Thewarach Laha, Istvan Toth, Alex Loukas

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Vaccine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Wuttipong PhumrattanaprapinPrincess Srisavangavadhana Faculty of Medicine, Chulabhorn Royal Academy, Bangkok 10210, Thailand. Electronic address: wuttipong.phu@cra.ac.th.
Ahmed O ShalashSchool of Chemistry and Molecular Biosciences, The University of Queensland, St Lucia, QLD 4072, Australia.
Mariusz SkwarczynskiSchool of Chemistry and Molecular Biosciences, The University of Queensland, St Lucia, QLD 4072, Australia.
Michael J SmoutAustralian Institute of Tropical Health and Medicine, James Cook University, Cairns, QLD 4878, Australia.
Thewarach LahaDepartment of Parasitology, Faculty of Medicine, Khon Kaen University, Khon Kaen 40002, Thailand.
Istvan TothSchool of Chemistry and Molecular Biosciences, The University of Queensland, St Lucia, QLD 4072, Australia.
Alex LoukasAustralian Institute of Tropical Health and Medicine, James Cook University, Cairns, QLD 4878, Australia.

Funding

Targeting parasite-host communication to combat liver fluke-induced bile duct cancerR01CA164719 · NCI · GEORGE WASHINGTON UNIVERSITY · PI Paul J Brindley, THEWARACH LAHA · 2012 to 2026
$5.0M
NCI NIH HHS R01 CA164719
6 · The paper itself

Abstract

objectivesChronic Opisthorchis viverrini infection is a major contributor to cholangiocarcinoma in Southeast Asia, necessitating effective vaccine development. This study aimed to evaluate the immunogenicity and protective efficacy of peptide-based oral vaccines targeting O. viverrini in a hamster model.

methodsFive protein fragments from the vaccine candidate antigen Ov-TSP-2 were synthesized, with LEL4 and SEL peptides identified as the most immunogenic. These peptides were conjugated to polymethylacrylate (PMA) for nanoparticle self-assembly and mucosal immunization. Hamsters received four oral immunizations and were challenged with O. viverrini metacercariae to assess immune response and protection.

resultsLEL4-immunized hamsters demonstrated elevated antigen-specific serum IgG, mucosal IgG, and IgA titers. This immune response correlated with significantly reduced egg counts and worm burdens. Recovered worms from vaccinated hamsters exhibited stunted growth, indicating impaired parasite development.

conclusionsThis study establishes the potential of LEL4 as a peptide-based oral vaccine against O. viverrini. By inducing mucosal and systemic immunity, the vaccine offers a promising strategy for combating opisthorchiasis and its associated cancer risk, marking a significant advancement in liver fluke control.

Indexed as

OpisthorchiasisOpisthorchisVaccines, SubunitAdministration, OralAnimalsAntibodies, HelminthAntigens, HelminthCricetinaeDisease Models, AnimalImmunity, MucosalImmunoglobulin GMesocricetusProtein Subunit VaccinesVaccine DevelopmentAntibodies, HelminthAntigens, HelminthImmunoglobulin GProtein Subunit VaccinesVaccines, Subunitcancer vaccineLiver flukeMucosal immunityNanoparticleOpisthorchis viverriniOral vaccinePeptide vaccinePolymethylacrylateTetraspanin

Identifiers

PMID40532477
PMCPMC12289465

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.